PerkinElmer Inc. (NYSE:PKI) made announcements on two software firm acquisition deals intended to expand its offerings for the pharmaceutical industry.
The Waltham, Mass.-based life science and health IT firm said it will spend about $220 million as it closed its deal on R&D software company ArtusLabs Inc. and announced an agreement to acquire CambridgeSoft Corp.
Durham, N.C.-based ArtusLabs’ software offers scientific data mining among other capabilities and is used by pharmaceutical industry researchers and others working in science-related research to crunch large amounts of data, according to PerkinElmer.
Cambridge, Mass.-based CambridgeSoft develops computational, database and drawing software for the pharmaceutical, biotechnology and chemical industries, according to the company.
The purchase price for both companies was not disclosed.
PerkinElmer CEO Robert Friel said in a prepared statement that the acquisition of both companies will boost the company’s capabilities in informatics-based research, related to collecting and managing data.
“The ability to integrate scientific tools and informatics is becoming increasingly critical for our customers as they look to drive productivity and speed to market,” Friel said.
PerkinElmer said 2011 revenue for ArtusLabs and CambridgeSoft is projected to reach $65 million.
ArtusLabs, founded in 2007, was backed by Durham venture capital firm Hatteras Venture Partners, among other investors who have pumped more than $4 million in investments into the company.